This report provides a comprehensive analysis of the global NAD+ IV therapy market, which is projected to experience significant growth through 2032. The study examines market dynamics as the industry transitions from a wellness-based concept toward a strictly regulated, clinically validated medical intervention. Key trends include increasing regulatory oversight, a heightened focus on pharmaceutical-grade safety standards, and the evolution of business models toward longitudinal medical management. Furthermore, the report evaluates competitive landscapes across various product types, applications, and geographic regions.

Market Overview

The global NAD+ IV Therapy market size is predicted to grow from US$ 97 million in 2025 to US$ 170 million in 2032, representing a compound annual growth rate (CAGR) of 8.6% from 2026 to 2032.

Definition: NAD+ IV Therapy is a wellness therapy involving the intravenous administration of nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for metabolic processes and cellular energy production. The therapy aims to boost energy levels, enhance cognitive function, and promote overall cellular repair by increasing NAD+ levels, which naturally decline as a result of aging.

Industry Research Scope

The "NAD+ IV Therapy Industry Forecast" by LPI (LP Information) reviews total global NAD+ IV Therapy sales in 2025 and provides a comprehensive analysis of projected sales for 2026 through 2032. The report includes:

• Detailed analysis in US$ millions of the global industry.
• Breakdowns by region, market sector, and sub-sector.
• Analysis of key trends regarding product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Evaluation of leading global companies, focusing on their NAD+ IV Therapy portfolios, capabilities, market entry strategies, market positions, and geographic footprints.
• Assessment of market drivers, trends, and affecting factors using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs.

Key Market Trends

1. Evidence-Driven Transition

The industry is shifting from concept-based anti-aging services toward clinically validated interventions. While current benefits (anti-fatigue, cognitive enhancement, metabolic optimization, and longevity) are largely supported by animal models, mechanistic studies, or small observational trials, increasing regulatory scrutiny will necessitate robust clinical evidence from large-scale randomized controlled trials (RCTs). The market is expected to evolve from loosely defined "anti-aging treatments" into medically framed interventions with specific use cases, patient stratification, and standardized clinical endpoints.

2. Regulatory Tightening

NAD+ IV therapy is moving from a semi-gray commercial zone into a strictly regulated medical framework. Currently delivered via medical spas, wellness clinics, or functional medicine centers—often without standardized drug registration or approved indications—the sector will face increased government control. Future requirements will include formal standards for drug sourcing, sterile preparation, clinical justification, physician supervision, and liability management. This shift is expected to raise entry barriers, favoring hospital systems and licensed clinics while eliminating low-compliance providers.

3. Safety and Quality Dominance

As the industry matures, safety and pharmaceutical-grade quality control will become the primary competitive axis. Due to the systemic risks of intravenous administration, there will be stringent demands on:

• Sterile manufacturing and endotoxin control
• Formulation stability and dosage consistency
• Cold-chain logistics
• GMP-level production, batch traceability, and sterility validation
• Adverse-event monitoring and standardized infusion procedures

4. Product Pathway Differentiation

Due to high operational costs, medical dependency, and administration time, NAD+ IV is unlikely to become a mass-market solution. Instead, it is expected to reposition as a premium, specialized niche within functional medicine, longevity clinics, and rehabilitation medicine. Meanwhile, larger market volumes will likely be captured by more scalable, standardized, and consumer-friendly non-IV alternatives, such as NAD+ precursors.

5. Business Model Evolution

The commercial model is transitioning from transaction-based "anti-aging packages" to longitudinal medical management systems. Leading providers will move away from simple service-selling toward integrated functional medicine frameworks that utilize baseline diagnostics, biomarker tracking, patient segmentation, and outcome monitoring. In this model, NAD+ IV serves as one component of a personalized health optimization ecosystem driven by continuous medical engagement and data accumulation.

Market Segmentation

By Type

• NAD+ Mixed Vitamin Injections
• Pure NAD+ Injection

By Injection

• Single-use Injection Type
• Recurring Injection Type
• Others

By Dose

• Low-dose Type
• Medium-dose Type
• High-dose Type

By Application

• Clinic
• Hospital
• Others

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key companies profiled in this report were selected based on primary expert input and analysis of company coverage, product portfolio, and market penetration:

• The Wellness Lab
• Conciergemdla
• Azivmedics
• Reset IV
• Thedripclub
• Toronto Functional Medicine Centre
• Mobileivmedics
• Rocky Mountain Ivmedics
• Premiumhealth
• Effect Doctors
• Nadclinic
• Hydrate IV Bar
• LIVV Natural
• BioReset Medical
• IV Boost UK

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global NAD+ IV Therapy Market Size (2021-2032)

    • 2.1.2 NAD+ IV Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for NAD+ IV Therapy by Country/Region (2021, 2025 & 2032)

  • 2.2 NAD+ IV Therapy Segment by Type

    • 2.2.1 NAD+ Mixed Vitamin Injections

    • 2.2.2 Pure NAD+ Injection

    • 2.2.3 NAD+ IV Therapy Market Size by Type

      • 2.2.3.1 NAD+ IV Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.3.2 Global NAD+ IV Therapy Market Size Market Share by Type (2021-2026)

  • 2.3 NAD+ IV Therapy Segment by Injection

    • 2.3.1 Single-use Injection Type

    • 2.3.2 Recurring Injection Type

    • 2.3.3 Others

    • 2.3.4 NAD+ IV Therapy Market Size by Injection

      • 2.3.4.1 NAD+ IV Therapy Market Size CAGR by Injection (2021 VS 2025 VS 2032)
      • 2.3.4.2 Global NAD+ IV Therapy Market Size Market Share by Injection (2021-2026)

  • 2.4 NAD+ IV Therapy Segment by Dose

    • 2.4.1 Low-dose Type

    • 2.4.2 Medium-dose Type

    • 2.4.3 High-dose Type

    • 2.4.4 NAD+ IV Therapy Market Size by Dose

      • 2.4.4.1 NAD+ IV Therapy Market Size CAGR by Dose (2021 VS 2025 VS 2032)
      • 2.4.4.2 Global NAD+ IV Therapy Market Size Market Share by Dose (2021-2026)

  • 2.5 NAD+ IV Therapy Segment by Application

    • 2.5.1 Clinic

    • 2.5.2 Hospital

    • 2.5.3 Others

    • 2.5.4 NAD+ IV Therapy Market Size by Application

      • 2.5.4.1 NAD+ IV Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.5.4.2 Global NAD+ IV Therapy Market Size Market Share by Application (2021-2026)

• 3 NAD+ IV Therapy Market Size by Player

  • 3.1 NAD+ IV Therapy Market Size Market Share by Player

    • 3.1.1 Global NAD+ IV Therapy Revenue by Player (2021-2026)

    • 3.1.2 Global NAD+ IV Therapy Revenue Market Share by Player (2021-2026)

  • 3.2 Global NAD+ IV Therapy Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 NAD+ IV Therapy by Region

  • 4.1 NAD+ IV Therapy Market Size by Region (2021-2026)

  • 4.2 Global NAD+ IV Therapy Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas NAD+ IV Therapy Market Size Growth (2021-2026)

  • 4.4 APAC NAD+ IV Therapy Market Size Growth (2021-2026)

  • 4.5 Europe NAD+ IV Therapy Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa NAD+ IV Therapy Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas NAD+ IV Therapy Market Size by Country (2021-2026)

  • 5.2 Americas NAD+ IV Therapy Market Size by Type (2021-2026)

  • 5.3 Americas NAD+ IV Therapy Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC NAD+ IV Therapy Market Size by Region (2021-2026)

  • 6.2 APAC NAD+ IV Therapy Market Size by Type (2021-2026)

  • 6.3 APAC NAD+ IV Therapy Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe NAD+ IV Therapy Market Size by Country (2021-2026)

  • 7.2 Europe NAD+ IV Therapy Market Size by Type (2021-2026)

  • 7.3 Europe NAD+ IV Therapy Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa NAD+ IV Therapy by Region (2021-2026)

  • 8.2 Middle East & Africa NAD+ IV Therapy Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa NAD+ IV Therapy Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global NAD+ IV Therapy Market Forecast

  • 10.1 Global NAD+ IV Therapy Forecast by Region (2027-2032)

    • 10.1.1 Global NAD+ IV Therapy Forecast by Region (2027-2032)

    • 10.1.2 Americas NAD+ IV Therapy Forecast

    • 10.1.3 APAC NAD+ IV Therapy Forecast

    • 10.1.4 Europe NAD+ IV Therapy Forecast

    • 10.1.5 Middle East & Africa NAD+ IV Therapy Forecast

  • 10.2 Americas NAD+ IV Therapy Forecast by Country (2027-2032)

    • 10.2.1 United States Market NAD+ IV Therapy Forecast

    • 10.2.2 Canada Market NAD+ IV Therapy Forecast

    • 10.2.3 Mexico Market NAD+ IV Therapy Forecast

    • 10.2.4 Brazil Market NAD+ IV Therapy Forecast

  • 10.3 APAC NAD+ IV Therapy Forecast by Region (2027-2032)

    • 10.3.1 China NAD+ IV Therapy Market Forecast

    • 10.3.2 Japan Market NAD+ IV Therapy Forecast

    • 10.3.3 Korea Market NAD+ IV Therapy Forecast

    • 10.3.4 Southeast Asia Market NAD+ IV Therapy Forecast

    • 10.3.5 India Market NAD+ IV Therapy Forecast

    • 10.3.6 Australia Market NAD+ IV Therapy Forecast

  • 10.4 Europe NAD+ IV Therapy Forecast by Country (2027-2032)

    • 10.4.1 Germany Market NAD+ IV Therapy Forecast

    • 10.4.2 France Market NAD+ IV Therapy Forecast

    • 10.4.3 UK Market NAD+ IV Therapy Forecast

    • 10.4.4 Italy Market NAD+ IV Therapy Forecast

    • 10.4.5 Russia Market NAD+ IV Therapy Forecast

  • 10.5 Middle East & Africa NAD+ IV Therapy Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market NAD+ IV Therapy Forecast

    • 10.5.2 South Africa Market NAD+ IV Therapy Forecast

    • 10.5.3 Israel Market NAD+ IV Therapy Forecast

    • 10.5.4 Turkey Market NAD+ IV Therapy Forecast

  • 10.6 Global NAD+ IV Therapy Forecast by Type (2027-2032)

  • 10.7 Global NAD+ IV Therapy Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market NAD+ IV Therapy Forecast

• 11 Key Players Analysis

  • 11.1 The Wellness Lab

    • 11.1.1 The Wellness Lab Company Information

    • 11.1.2 The Wellness Lab NAD+ IV Therapy Product Offered

    • 11.1.3 The Wellness Lab NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 The Wellness Lab Main Business Overview

    • 11.1.5 The Wellness Lab Latest Developments

  • 11.2 Conciergemdla

    • 11.2.1 Conciergemdla Company Information

    • 11.2.2 Conciergemdla NAD+ IV Therapy Product Offered

    • 11.2.3 Conciergemdla NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Conciergemdla Main Business Overview

    • 11.2.5 Conciergemdla Latest Developments

  • 11.3 Azivmedics

    • 11.3.1 Azivmedics Company Information

    • 11.3.2 Azivmedics NAD+ IV Therapy Product Offered

    • 11.3.3 Azivmedics NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Azivmedics Main Business Overview

    • 11.3.5 Azivmedics Latest Developments

  • 11.4 Reset IV

    • 11.4.1 Reset IV Company Information

    • 11.4.2 Reset IV NAD+ IV Therapy Product Offered

    • 11.4.3 Reset IV NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Reset IV Main Business Overview

    • 11.4.5 Reset IV Latest Developments

  • 11.5 Thedripclub

    • 11.5.1 Thedripclub Company Information

    • 11.5.2 Thedripclub NAD+ IV Therapy Product Offered

    • 11.5.3 Thedripclub NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Thedripclub Main Business Overview

    • 11.5.5 Thedripclub Latest Developments

  • 11.6 Toronto Functional Medicine Centre

    • 11.6.1 Toronto Functional Medicine Centre Company Information

    • 11.6.2 Toronto Functional Medicine Centre NAD+ IV Therapy Product Offered

    • 11.6.3 Toronto Functional Medicine Centre NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Toronto Functional Medicine Centre Main Business Overview

    • 11.6.5 Toronto Functional Medicine Centre Latest Developments

  • 11.7 Mobileivmedics

    • 11.7.1 Mobileivmedics Company Information

    • 11.7.2 Mobileivmedics NAD+ IV Therapy Product Offered

    • 11.7.3 Mobileivmedics NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Mobileivmedics Main Business Overview

    • 11.7.5 Mobileivmedics Latest Developments

  • 11.8 Rocky Mountain Ivmedics

    • 11.8.1 Rocky Mountain Ivmedics Company Information

    • 11.8.2 Rocky Mountain Ivmedics NAD+ IV Therapy Product Offered

    • 11.8.3 Rocky Mountain Ivmedics NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Rocky Mountain Ivmedics Main Business Overview

    • 11.8.5 Rocky Mountain Ivmedics Latest Developments

  • 11.9 Premiumhealth

    • 11.9.1 Premiumhealth Company Information

    • 11.9.2 Premiumhealth NAD+ IV Therapy Product Offered

    • 11.9.3 Premiumhealth NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Premiumhealth Main Business Overview

    • 11.9.5 Premiumhealth Latest Developments

  • 11.10 Effect Doctors

    • 11.10.1 Effect Doctors Company Information

    • 11.10.2 Effect Doctors NAD+ IV Therapy Product Offered

    • 11.10.3 Effect Doctors NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Effect Doctors Main Business Overview

    • 11.10.5 Effect Doctors Latest Developments

  • 11.11 Nadclinic

    • 11.11.1 Nadclinic Company Information

    • 11.11.2 Nadclinic NAD+ IV Therapy Product Offered

    • 11.11.3 Nadclinic NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Nadclinic Main Business Overview

    • 11.11.5 Nadclinic Latest Developments

  • 11.12 Hydrate IV Bar

    • 11.12.1 Hydrate IV Bar Company Information

    • 11.12.2 Hydrate IV Bar NAD+ IV Therapy Product Offered

    • 11.12.3 Hydrate IV Bar NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Hydrate IV Bar Main Business Overview

    • 11.12.5 Hydrate IV Bar Latest Developments

  • 11.13 LIVV Natural

    • 11.13.1 LIVV Natural Company Information

    • 11.13.2 LIVV Natural NAD+ IV Therapy Product Offered

    • 11.13.3 LIVV Natural NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 LIVV Natural Main Business Overview

    • 11.13.5 LIVV Natural Latest Developments

  • 11.14 BioReset Medical

    • 11.14.1 BioReset Medical Company Information

    • 11.14.2 BioReset Medical NAD+ IV Therapy Product Offered

    • 11.14.3 BioReset Medical NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 BioReset Medical Main Business Overview

    • 11.14.5 BioReset Medical Latest Developments

  • 11.15 IV Boost UK

    • 11.15.1 IV Boost UK Company Information

    • 11.15.2 IV Boost UK NAD+ IV Therapy Product Offered

    • 11.15.3 IV Boost UK NAD+ IV Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 IV Boost UK Main Business Overview

    • 11.15.5 IV Boost UK Latest Developments

• 12 Research Findings and Conclusion